Infectious Disease / Microbiology Updates
6.65K subscribers
31 photos
3 videos
23 files
3.73K links
All the atest articles, research and news from worlds leading Infectious Disease Journals.

Discussion group
https://t.me/Professional_Medical_Discussion
Download Telegram
[Articles] Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00241-3/fulltext?rss=yes

Acceptability and tolerability of intramuscular cabotegravir–rilpivirine remained high through to 48 weeks of treatment, suggesting that this long-acting intramuscular treatment approach is well received by diverse populations of adolescents with HIV across multiple settings.
2
[Articles] Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00242-5/fulltext?rss=yes

Week 48 data from the first virologically suppressed adolescents with HIV-1 who switched from daily oral to intramuscular cabotegravir and intramuscular rilpivirine every 8 weeks showed favourable safety, pharmacokinetics, and virological suppression informing both real-world use, where approved, and ongoing regulatory submissions, where approval is pending.